Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics reported a net loss of $32.8 million or ($0.82) per share for Q3 2020, compared to a $23.9 million loss in Q3 2019. Research and development expenses rose to $21.0 million, while general and administrative costs increased to $11.6 million.
Despite the financial losses, Y-mAbs is progressing with its pipeline, including a planned resubmission of the omburtamab BLA and advancements in nivatrotamab, which received Orphan Drug and Rare Pediatric Disease designations from the FDA.
- Nivatrotamab received Orphan Drug Designation and Rare Pediatric Disease Designation from FDA.
- FDA cleared Investigational New Drug application for 177Lu-omburtamab-DTPA targeting medulloblastoma and B7-H3 positive CNS lesions.
- Plans to resubmit omburtamab BLA by end of 2020 or early 2021, following a recent positive Type A meeting with the FDA.
- Net loss increased to $32.8 million in Q3 2020, up from $23.9 million in Q3 2019.
- General and administrative expenses surged by $6.9 million compared to Q3 2019.
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter 2020.
“We are very pleased with our third quarter 2020 financial results, especially seen in conjunction with the upcoming
PDUFA date for naxitamab later this month, and the planned resubmission of the omburtamab BLA. We believe that we are well positioned to transform Y-mAbs to a commercial-stage company,” stated Thomas Gad, founder, Chairman and President.
Dr. Claus Moller, Chief Executive Officer, continued, “We are making good progress on the omburtamab BLA resubmission, and concurrently we’ve continued to advance many of the earlier stage programs in our pipeline. Nivatrotamab, our leading bispecific antibody, recently received ODD and RPDD from the FDA and our two INDs for 177Lu-omburtamab-DTPA in medulloblastoma and B7-H3 positive CNS/leptomeningeal metastasis in adults were recently cleared by the FDA.”
Third Quarter 2020 and Recent Corporate Developments
- Subsequent to the end of the third quarter, on October 26, 2020 Y-mAbs announced that the FDA has cleared the Company’s IND for 177Lu-omburtamab-DTPA for the treatment of B7-H3 positive CNS and Leptomeningeal Metastasis from tumors in adult patients
- Also subsequent to the end of the third quarter, on October 16, 2020, Y-mAbs announced updates on naxitamab and omburtamab data, which were presented at the International Society of Pediatric Oncology conference
- Also subsequent to the end of the third quarter, on October 14, 2020 Y-mAbs announced that the FDA has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer in children
- Also subsequent to the end of the third quarter, on October 7, 2020, Y-mAbs announced that the FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation for its leading bispecific antibody product candidate nivatrotamab for the treatment of neuroblastoma
- After the close of the third quarter, on October 5, 2020, Y-mAbs announced that it had received a Refusal to File letter from the FDA for the omburtamab BLA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. Subsequently, Y-mAbs requested and received what it believes to have been a positive Type A meeting with the FDA, and plans to work in close dialog with the Agency to amend the BLA with the goal of resubmitting by the end of 2020 or in early 2021. The BLA was originally submitted in August 2020
- On July 14, 2020, Y-mAbs announced an update on the SADA technology and presented B7-H3 as a new preclinical SADA construct with potential use in prostate cancer
Financial Results
Y-mAbs reported a net loss of
For the nine months ended September 30, 2020, Y-mAbs reported a net loss of
Operating Expenses
Research and Development
Research and development expenses were
$2.4 million increase in personnel costs;$0.5 million increase in clinical trial expenses;$0.4 million increase in professional and consulting fees; and$2.0 million offsetting decrease in outsourced manufacturing cost
Research and development expenses were
$13.3 million increase in milestones and license fees related to the SADA upfront cash payment and stock issuances and accrued milestones;$6.3 million increase in personnel costs; and$1.9 million increase in outsourced research and supplies to support the expansion of our product development activities
General and Administration
General and administrative expenses were
$3.2 million increase in commercial infrastructure costs;$2.2 million increase in personnel costs; and$1.6 million increase in business insurance and professional fees
General and administrative expenses were
$8.7 million increase in commercial infrastructure costs;$5.8 million increase in personnel costs; and$3.1 million increase in business insurance and professional fees
Cash and Cash Equivalents
The Company had approximately
Webcast and Conference Call
The Company will host a conference call on Friday, November 6, 2020 at 9 a.m. Eastern Time. To participate in the call, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and reference the access code 13712633. A webcast will be available at: http://public.viavid.com/index.php?id=142256
About Y-mAbs
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development and commercialization plans; current and future clinical and pre-clinical studies and our research and development programs; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ “appear,” ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Annual Report on Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
“Y-mAbs” is a registered trademark of Y-mAbs Therapeutics, Inc.
| Y-MABS THERAPEUTICS, INC. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (unaudited) | ||||||||
| (in thousands, except share data) | ||||||||
| September 30, | December 31, | |||||||
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 131,267 | $ | 207,136 | ||||
| Other current assets | 1,942 | 4,819 | ||||||
| Total current assets | 133,209 | 211,955 | ||||||
| Property and equipment, net | 1,888 | 2,052 | ||||||
| Operating lease right-of-use assets | 5,123 | 1,989 | ||||||
| Other assets | 2,975 | 370 | ||||||
| TOTAL ASSETS | $ | 143,195 | $ | 216,366 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| LIABILITIES | ||||||||
| Accounts payable | $ | 10,320 | $ | 8,520 | ||||
| Accrued liabilities | 7,570 | 4,550 | ||||||
| Operating lease liabilities, current portion | 1,887 | 516 | ||||||
| Total current liabilities | 19,777 | 13,586 | ||||||
| Accrued milestone and royalty payments | 2,466 | 1,921 | ||||||
| Operating lease liabilities, long-term portion | 2,517 | 1,714 | ||||||
| Other liabilities | 1,923 | 242 | ||||||
| TOTAL LIABILITIES | 26,683 | 17,463 | ||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred stock, | ||||||||
| September 30, 2020 and December 31, 2019; none issued at | ||||||||
| September 30, 2020 and December 31, 2019 | — | — | ||||||
| Common stock, | ||||||||
| September 30, 2020 and December 31, 2019; 40,472,435 and 39,728,416 | ||||||||
| shares issued at September 30, 2020 and December 31, 2019, respectively | 4 | 4 | ||||||
| Additional paid in capital | 381,803 | 364,712 | ||||||
| Accumulated other comprehensive income / (loss) | (28 | ) | 50 | |||||
| Accumulated deficit | (265,267 | ) | (165,863 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 116,512 | 198,903 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 143,195 | $ | 216,366 | ||||
| Y-MABS THERAPEUTICS, INC. | |||||||||||||||||
| Consolidated Statements of Net Loss and Comprehensive Loss | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||
| Three months ended September 30 | Nine months ended September 30 | ||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||
| OPERATING EXPENSES | |||||||||||||||||
| Research and development | $ | 21,005 | $ | 19,660 | $ | 69,686 | $ | 46,665 | |||||||||
| General and administrative | 11,636 | 4,699 | 30,155 | 12,581 | |||||||||||||
| Total operating expenses | 32,641 | 24,359 | 99,841 | 59,246 | |||||||||||||
| Loss from operations | (32,641 | ) | (24,359 | ) | (99,841 | ) | (59,246 | ) | |||||||||
| OTHER INCOME | |||||||||||||||||
| Interest and other income, net | (191 | ) | 437 | 437 | 1,354 | ||||||||||||
| NET LOSS | $ | (32,832 | ) | $ | (23,922 | ) | $ | (99,404 | ) | $ | (57,892 | ) | |||||
| Other comprehensive income / (loss) | |||||||||||||||||
| Foreign currency translation | (12 | ) | 134 | (78 | ) | 124 | |||||||||||
| COMPREHENSIVE LOSS | $ | (32,844 | ) | $ | (23,788 | ) | $ | (99,482 | ) | $ | (57,768 | ) | |||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.82 | ) | $ | (0.70 | ) | $ | (2.49 | ) | $ | (1.69 | ) | |||||
| Weighted average common shares outstanding, basic and diluted | 40,187,173 | 34,371,927 | 39,971,766 | 34,253,739 | |||||||||||||
Contact:
Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA
+1 646 885 8505
E-mail: info@ymabs.com
FAQ
What is Y-mAbs' financial result for Q3 2020?
What were the research and development expenses in Q3 2020 for YMAB?
What significant designations were granted to nivatrotamab?
What is the planned timeline for the omburtamab BLA resubmission?
